A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Tucatinib
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo Company, Limited